1,4-benzodiazepin-2-ones in medicinal chemistry

Future Medicinal Chemistry

Volumn 2, Issue 9, 2010, Pages 1441-1449

  Spencer, John ^a   Rathnam, Rajendra P ^a   Chowdhry, Babur Z ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTINEOPLASTIC AGENT; BENZODIAZEPIN 2 ONE DERIVATIVE; BZ 423; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; ENZYME INHIBITOR; FLUNITRAZEPAM; FLURAZEPAM; G PROTEIN COUPLED RECEPTOR; GAMMA SECRETASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LORAZEPAM; OXAMFLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TARGETING; LYMPHOMA CELL; MEDICINAL PLANT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SOLID STATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

BENZODIAZEPINES; HUMANS;

EID: 77956573599     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.226     Document Type: Short Survey

References (70)

1. Sternbach LH. 1,4-benzodiazepines. Chemistry and some aspects of the structure-activity relationship. Angew. Chem. Int. Ed. Engl. 10, 34-43 (1971).
2. Sternbach LH. Benzodiazepine story. J. Med. Chem. 22, 1-7 (1979).
3. Sternbach LH. The benzodiazepine story. J. Psychoactive Drugs 15, 15-17 (1983).
4. Hamor TA, Martin, IL, West GP, Ellis GB. The benzodiazepines. In: Progress in Medicinal Chemistry (Volume 20). Elsevier, NY, USA, 157-223 (1983).
5. Taylor D. Current usage of benzodiazepines in Britain. In: The Benzodiazepines in Current Clinical Practice. Freeman H, Rue Y (Eds). Royal Society of Medicine Services, London, UK, 13-18 (1987).
6. Harvey SC. Hypnotics and sedatives. In: Goodman Gilman's The Pharmacological Basis of Therapeutics (7th Edition). Gilman LS, Rall TW, Murad F (Eds). MacMillan, NY, USA, 339-386 (1985).
7. King MB. Is there still a role for benzodiazepines in general practice? Br. J. Gen. Pract. 42, 202-205 (1992).
8. Ashton CH. The Benzodiazepines: How They Work and How to Withdraw. Churchill Livingstone, Edinburgh, UK (2002).
9. A receptor subtype functions: the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 90, 37-42 (2008).
10. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol. Ther. 75, 199-216 (1997).
11. James ML, Selleri S, Kassiou M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem. 13, 1991-2001 (2006).
12. Holmes GL. Buccal route for benzodiazepines in treatment of seizures? Lancet 353, 608-609 (1999).
13. Curran H V. Benzodiazepines, memory and mood: a review. Psychopharmacology 105, 1-8 (1991).
14. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49-56 (2005).
15. Makhlouf MM, Ayoub AI, Abdel-Fattah MM. Insomnia symptoms and their correlates among the elderly in geriatric homes in Alexandria, Egypt. Sleep Breath. 11, 187-194 (2007).
16. Kryger M, Monjan A, Bliwise D et al. Sleep, health, and aging. Bridging the gap between science and clinical practice. Geriatrics 59, 24-26, 29-30 (2004).
17. Stokes TSE, Juarez-Garcia A, Camosso-Stefnovic J, Baker R. Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. Royal College of General Practitioners, London, UK (2004).
18. Barnard EA, Skolnick P, Olsen RW et al. International Union of Pharmacology. XV. Subtypes of g-butyric acid A receptors:classifcation on the basis of subunit structure and receptor function. Pharmacol. Rev. 50 (2), 291-313 (1998).
19. Myrick H, Anton RF. Treatment of alcohol withdrawal. Alcohol Health Res. World 22(1), 38-43 (1998).
20. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 16, 49-57 (1996).
21. 2 receptor antagonists. Expert Opin. Ther. Pat. 11(3), 445-462 (2001).
22. Evans BE, Rittle KE, Bock MG, DiPardo RM. Methods for drug discovery: development of potent, selective, orally effective cholescystokinin antagonists. J. Med. Chem. 31, 2235-2246 (1988).
23. Bock MG, DiPardo RM, Evans BE, Rittle KE. Synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 52, 3232-3239 (1987).
24. Dourlat J, Liu WQ, Gresh N, Garbay C. Novel 1,4-benzodiazepine derivatives with antiproliferative properties on tumor cell lines. Bioorg. Med. Chem. Lett. 17, 2527-2530 (2007).
25. Cheng P, Zhang Q, Ma YB et al. Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloroquinolin-2-one and 5-aryl-7-chloro-1,4- benzodiazepine derivatives. Bioorg. Med. Chem. Lett. 18, 3787-3789 (2008).
26. Boitano A, Emal CD, Leonetti F et al. Structure activity studies of a novel cytotoxic benzodiazepine. Bioorg. Med. Chem. Lett. 13, 3327-3330 (2003).
27. Cleary J, Johnson KM, Opipari AW, Glick GD. Inhibition of the mitochondrial F1Fo-ATPase by ligands of the peripheral benzodiazepine receptor. Bioorg. Med. Chem. Lett. 17, 1667-1670 (2007).
28. Boitano A, Ellman JA, Glick GD, Opipari AW. The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells. Cancer Res. 63, 6870-6876 (2003).
29. Sundberg TB, Ney GM, Subramanian C et al. The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-Myc protein for rapid and specifc degradation. Cancer Res. 66, 1775-1782 (2006).
30. Bhagavathula N, Nerusu KC, Hanosh A, Aslam MN. 7-chloro-5-(4- hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4] diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodefcient mouse transplant model. J. Pharmacol Exp. Ther. 324, 938-947 (2008).
31. Kim K, Volkman SK, Ellman JA. Synthesis of 3-substituted 1,4-benzodiazepin-2-ones. J. Braz. Chem. Soc. 9 (4), 375-379 (1998). (Pubitemid 128538234)
32. Guandalini L, Cellai C, Laurenzana A et al. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Bioorg. Med. Chem. Lett. 18, 5071-5074 (2008).
33. Micale N, Vairagoundar R, Yakovlev AG et al. Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J. Med. Chem. 47, 6455-6458 (2004).
34. Micale N, Kozikowski A P, Ettari R et al. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J. Med. Chem. 49, 3064-3067 (2006).
35. Ettari R, Micale N, SchirmeisterT et al. Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J. Med. Chem. 52, 2157-2160 (2009)
36. Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev. 103, 893-930 (2003).
37. Burgey CS, Stump CA, Nguyen DN et al. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine. Bioorg. Med. Chem. Lett. 16, 5052-5056 (2006).
38. Williams TM, Stump CA, Nguyen DN et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg. Med. Chem. Lett. 16, 2595-2598 (2006).
39. Wood MR, Kim JJ, Han W et al. Benzodiazepines as potent and selective bradykinin B1 antagonists. J. Med. Chem. 46, 1803-1806 (2003).
40. Bolli MH, Marfurt J, Grisostomi C et al. Novel benzo [1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J. Med. Chem. 47, 2776-2795 (2004).
41. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl Acad. Sci. USA 86, 2863-2867 (1989).
42. Owens AP, Nadin A, Talbot AC et al. High affnity, bioavailable 3-amino-1,4-benzodiazepin-based g-secretase inhibitors. Bioorg. Med. Chem. Lett. 13, 4143-4145 (2003).
43. Churcher I, Williams S, Kerrad S et al. Design and synthesis of highly potent benzodiazepine g-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difuorophenyl)-2-(4-fuorophenyl)-4-hydroxy-N-((3S) -1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. J. Med. Chem. 46, 2275-2278 (2003).
44. Nadin A, Lopez JMS, Owens AP et al. New synthesis of 1,3-dihydro-1,4- benzodiazepin-2(2H)-ones and 3-amino-1,3-dihydro-1,4-benzodiazepin-2(2H)-ones: Pd-catalyzed cross-coupling of imidoyl chlorides with organoboronic acids. J. Org. Chem. 68, 2844-2852 (2003).
45. Safaei-Ghomi J, Hatami A. Facile and effcient one-pot protocol for synthesis of 5-phenyl-1,4-benzodiazepin-2-one derivatives. Synth. Comm. 38, 297-302 (2008).
46. Wu C, Biediger RJ, Kogan TP. A highly practical route to 7-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one from p-anisidine. Synth. Comm. 29, 3509-3516 (1999).
47. Laustsen LS, Sams CK. Parallel synthesis of 1,3-dihydro-1,4- benzodiazepin-2-ones employing catch and release. J. Comb. Chem. 9, 1094-1103 (2007).
48. Wiklund P, Bergman J. Ring forming reactions of imines of 2-aminobenzaldehyde and related compounds. Org. Biomol. Chem. 1, 367-372 (2003).
49. Dewitt SH, Kiely JS, Stankovic CJ et al. Diversomers-an approach to nonpeptide, nonoligomeric chemical diversity. Proc. Natl Acad. Sci. USA 90, 6909-6913 (1993).
50. Bunin BA, Plunkett MJ, Ellman JA. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. Proc. Natl Acad. Sci. USA 91, 4708-4712 (1994).
51. Plunkett MJ, Ellman JA. A silicon-based linker for traceless solid-phase synthesis. J. Org. Chem. 60, 6006-6007 (1995).
52. Plunkett MJ, Ellman JA. Solid-phase synthesis of structurally diverse 1,4-benzodiazepine derivatives using the Stille coupling reaction. J. Am. Chem. Soc. 117, 3306-3307 (1995).
53. Plunkett MJ, Ellman JA. Germanium and silicon linking strategies for traceless solid-phase synthesis. J. Org. Chem. 62, 2885-2893 (1997).
54. Spulak M, Lubojacky R, Senel P et al. Direct C-H arylation and alkenylation of 1-substituted tetrazoles: phosphine as stabilizing factor. J. Org. Chem. 75, 241-244 (2010).
55. Lebrasseur N, Larrosa I. Room temperature and phosphine free palladium catalyzed direct C-2 arylation of indoles. J. Am. Chem. Soc. 130, 2926-2927 (2008).
56. Li BJ, Tian SL, Fang Z et al. Multiple C-H activations to construct biologically active molecules in a process completely free of organohalogen and organometallic components. Angew. Chem. Int. Ed. 120, 1131-1134 (2008).
57. Stuart DR, Fagnou K. The catalytic cross-coupling of unactivated arenas. Science 316, 1172-1175 (2007).
58. Spencer J, Chowdhry BZ, Mallet AI et al. C-H activations on a 1H-1,4-benzodiazepin-2(3H)-one template. Tetrahedron 64, 6082-6089 (2008)
59. Gribble M W, Ellman JA, Bergman RG. Synthesis of a benzodiazepine-derived rhodium NHC complex by C-H bond activation. Organometallics 27, 2152-2155 (2008).
60. Yotphan S, Bergman RG, Ellman JA. Application of Daugulis copper-catalyzed direct arylation to the synthesis of 5-aryl benzotriazepines. Org. Lett. 61, 1511-1514 (2009).
61. 1 receptors. J. Med. Chem. 49(7), 2253-2261 (2006).
62. 2 antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion. J. Med. Chem. 50(13), 3101-3112 (2007).
63. 2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template. Bioorg. Med. Chem. 16, 2974-2983 (2008).
64. McDonald IM, Austin C, Buck IM et al. Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists. J. Med. Chem. 50(20), 4789-4792 (2007).
65. Spencer J, Sharratt DP, Dupont J et al. Synthesis and evaluation of 5-phenyl-1H-1,4-benzodiazepin-2(3H)-one-based palladium complexes as precatalysts in C-C bond forming reactions. Organometallics 24, 5665-5672 (2005).
66. Spencer J, Rathnam R P, Motukuri M et al. Synthesis of a 1,4-benzodiazepine containing palladacycle with in vitro anticancer and cathepsin B activity. Dalton Trans. 22, 4299-4303 (2009).
67. Spencer J, Casini A, Zava O et al. Excellent correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles. Dalton Trans. 48, 10731-10735 (2009).
68. Costantino L, Barlocco D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 13, 65-85 (2006).
69. Spencer J. Microwave chemistry enabling the synthesis of biologically relevant amines. Future Med. Chem. 2(2), 161-168 (2010).
70. Armour DR, Aston N, Morriss et al. 1,4-benzodiazepin-2-one derived neurokinin-1 receptor antagonists. Bioorg. Med. Chem. Lett. 7(15), 2037-2042 (1997).